Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumabHagström, Emil; Steg, P. Gabriel; Szarek, Michael; Bhatt, Deepak L.; Bittner, Vera A.; Danchin, Nicolas; Diaz, Rafael; Goodman, Shaun G.; Harrington, Robert A.; Jukema, J. Wouter; Liberopoulos, Evangelos; Marx, Nikolaus; Viigimaa, MargusCirculation2022 / p. 657 - 672 https://doi.org/10.1161/CIRCULATIONAHA.121.057807 Journal metrics at Scopus Article at Scopus Journal metrics at WOS Article at WOS

Darapladib for preventing ischemic events in stable coronary heart diseaseWhite, Harvey D.; Held, Claes; Stewart, Ralph; Tarka, Elizabeth; Brown, Rebekkah; Davies, Richard Y.; Budaj, Andrzej; Harrington, Robert A.; Steg, P. Gabriel; Viigimaa, MargusNew England journal of medicine2014 / p. 1702-1711 https://doi.org/10.1056/NEJMoa1315878 Journal metrics at Scopus Article at Scopus Journal metrics at WOS Article at WOS

Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart diseaseWallentin, Lars; Held, Claes; Armstrong, Paul W.; Cannon, Christopher Paul; Davies, Richard Y.; Granger, Christopher B.; Hagström, Emil; Harrington, Robert A.; Viigimaa, MargusJournal of the American Heart Association2016 / art. e003407 https://doi.org/10.1161/JAHA.116.003407 Journal metrics at Scopus Article at Scopus Journal metrics at WOS Article at WOS